About XBiotech (NASDAQ:XBIT)
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2930
Debt
Debt-to-Equity RatioN/A
Current Ratio11.95%
Quick Ratio11.95%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book2.85
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-33,150,000.00
Net MarginsN/A
Return on Equity-46.91%
Return on Assets-44.34%
Miscellaneous
Employees51
Outstanding Shares35,440,000
XBiotech (NASDAQ:XBIT) Frequently Asked Questions
What is XBiotech's stock symbol?
XBiotech trades on the NASDAQ under the ticker symbol "XBIT."
How were XBiotech's earnings last quarter?
XBiotech (NASDAQ:XBIT) issued its quarterly earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.08. View XBiotech's Earnings History.
When is XBiotech's next earnings date?
What price target have analysts set for XBIT?
2 analysts have issued twelve-month price objectives for XBiotech's stock. Their forecasts range from $13.00 to $13.00. On average, they anticipate XBiotech's share price to reach $13.00 in the next year. View Analyst Ratings for XBiotech.
Who are some of XBiotech's key competitors?
Some companies that are related to XBiotech include Catalyst Biosciences (CBIO), AVEO Pharmaceuticals (AVEO), Merus (MRUS), Zymeworks (ZYME), Aquinox Pharmaceuticals (AQXP), BioSpecifics Technologies (BSTC), Celyad (CYAD), Arbutus Biopharma (ABUS), Avadel Pharmaceuticals (AVDL), Selecta Biosciences (SELB), Savara (SVRA), Minerva Neurosciences (NERV), Syndax Pharmaceuticals (SNDX), ArQule (ARQL), Kindred Biosciences (KIN), Catalyst Pharmaceuticals (CPRX), Bellicum Pharmaceuticals (BLCM) and resTORbio (TORC).
Who are XBiotech's key executives?
XBiotech's management team includes the folowing people:
- Mr. John Simard, Founder, Chairman, Chief Exec. Officer and Pres (Age 56)
- Dr. Michael Stecher M.D., Medical Director (Age 41)
- Ms. Queena Han, VP of Fin. & HR and Sec. (Age 51)
- Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 62)
- Dr. Sushma Shivaswamy Ph.D., Chief Scientific Officer (Age 40)
When did XBiotech IPO?
(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.
Has XBiotech been receiving favorable news coverage?
News headlines about XBIT stock have trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XBiotech earned a daily sentiment score of 0.09 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.89 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of XBiotech?
Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XBiotech's stock price today?
One share of XBIT stock can currently be purchased for approximately $4.84.
How big of a company is XBiotech?
XBiotech has a market capitalization of $169.40 million. XBiotech employs 51 workers across the globe.
How can I contact XBiotech?
XBiotech's mailing address is 8201 E. RIVERSIDE DRIVE BUILDING 4 SUITE 100, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2930 or via email at [email protected]
MarketBeat Community Rating for XBiotech (XBIT)
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
XBiotech (NASDAQ:XBIT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for XBiotech in the last 12 months. Their average twelve-month price target is $13.00, suggesting that the stock has a possible upside of 168.60%. The high price target for XBIT is $13.00 and the low price target for XBIT is $13.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.00 | $13.00 | $13.00 | $13.00 |
| Price Target Upside: | 168.60% upside | 27.33% upside | 27.33% upside | 27.33% upside |
XBiotech (NASDAQ:XBIT) Consensus Price Target History
XBiotech (NASDAQ:XBIT) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
XBiotech (NASDAQ:XBIT) Earnings History and Estimates Chart
XBiotech (NASDAQ XBIT) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2018 | | | | | | | | |
| 5/10/2017 | Q1 2017 | ($0.47) | ($0.32) | | | View | N/A |  |
| 3/16/2017 | Q4 2016 | ($0.42) | ($0.51) | | | View | N/A | |
| 11/14/2016 | Q3 2016 | ($0.46) | ($0.38) | | | View | Listen | |
| 8/12/2016 | Q2 2016 | ($0.35) | ($0.42) | | | View | N/A | |
| 5/18/2016 | Q1 2016 | ($0.39) | ($0.32) | | | View | N/A | |
| 3/30/2016 | Q4 2015 | ($0.35) | ($0.37) | | | View | N/A | |
| 11/12/2015 | Q3 | ($0.21) | ($0.33) | | | View | Listen | |
| 8/14/2015 | Q2 2015 | | ($0.22) | | | View | N/A | |
| 5/27/2015 | Q1 2015 | | ($0.29) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
XBiotech (NASDAQ:XBIT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
XBiotech (NASDAQ XBIT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 9.36%
XBiotech (NASDAQ XBIT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/23/2018 | Queena Han | VP | Sell | 80,000 | $4.73 | $378,400.00 | 9,599 | |
| 3/21/2018 | Queena Han | VP | Sell | 9,599 | $4.48 | $43,003.52 | 9,599 | |
| 11/15/2016 | Queena Han | VP | Sell | 19,573 | $15.00 | $293,595.00 | 19,573 | |
| 9/8/2016 | Queena Han | VP | Sell | 427 | $15.00 | $6,405.00 | 427 | |
| 5/26/2016 | W Thorpe Mckenzie | Director | Buy | 20,000 | $13.96 | $279,200.00 | 3,898,600 | |
| 5/20/2016 | W Thorpe Mckenzie | Director | Buy | 1,500 | $13.75 | $20,625.00 | 3,898,600 | |
| 12/22/2015 | Queena Han | VP | Sell | 30,000 | $10.39 | $311,700.00 | | |
| 11/16/2015 | Michael Stecher | Director | Sell | 1,800 | $14.00 | $25,200.00 | | |
(Data available from 1/1/2013 forward)
XBiotech (NASDAQ XBIT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology
www.reuters.com - April 16 at 9:37 AM |
 | XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology
finance.yahoo.com - April 16 at 9:37 AM |
 | XBiotech (XBIT) Announces License from CT Atlantic AG for Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
www.streetinsider.com - April 3 at 10:01 AM |
 | XBiotech, Inc: XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
www.finanznachrichten.de - April 2 at 10:10 AM |
| XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
finance.yahoo.com - April 2 at 10:10 AM |
 | Insider Selling: XBiotech Inc (XBIT) VP Sells 9,599 Shares of Stock
www.americanbankingnews.com - March 26 at 4:12 PM |
| Queena Han Sells 80,000 Shares of XBiotech Inc (XBIT) Stock
www.americanbankingnews.com - March 26 at 4:10 PM |
| Comparing Athenex (ATNX) & XBiotech (XBIT)
www.americanbankingnews.com - March 3 at 7:22 PM |
| Active-Investors: Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF Conference
www.finanznachrichten.de - January 29 at 4:34 PM |
| Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF Conference
finance.yahoo.com - January 29 at 9:05 AM |
| XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
finance.yahoo.com - January 26 at 9:04 AM |
| XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus
finance.yahoo.com - January 25 at 8:59 AM |
| Blog Exposure - XBiotech to Present Phase-2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa at EHSF Conference
finance.yahoo.com - January 22 at 5:39 PM |
 | XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment ... - GlobeNewswire (press release)
globenewswire.com - January 19 at 12:00 PM |
| XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
finance.yahoo.com - January 19 at 12:00 PM |
| Financial Analysis: XBiotech (XBIT) vs. Its Peers
www.americanbankingnews.com - January 7 at 7:28 AM |
 | Winners, losers: The 5 best and 5 worst performing Austin-area stocks of 2017
www.bizjournals.com - January 6 at 10:25 AM |
| Cynapsus Therapeutics (CYNA) & XBiotech (XBIT) Head-To-Head Comparison
www.americanbankingnews.com - January 3 at 5:34 PM |
| Analyzing XBiotech (XBIT) and Its Competitors
www.americanbankingnews.com - January 1 at 3:28 AM |
| Reviewing XBiotech (XBIT) & The Competition
www.americanbankingnews.com - December 29 at 7:24 PM |
| Financial Contrast: XBiotech (XBIT) vs. Its Rivals
www.americanbankingnews.com - December 19 at 7:10 PM |
| Short Interest in XBiotech Inc. (XBIT) Decreases By 2.2%
www.americanbankingnews.com - December 18 at 4:36 PM |
| Contrasting XBiotech (XBIT) & Revance Therapeutics (RVNC)
www.americanbankingnews.com - December 17 at 1:50 AM |
| The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
finance.yahoo.com - December 11 at 4:38 PM |
| Critical Analysis: XBiotech (XBIT) & Its Rivals
www.americanbankingnews.com - December 11 at 8:08 AM |
| Critical Review: XBiotech (XBIT) versus Its Peers
www.americanbankingnews.com - December 9 at 7:18 PM |
| XBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study
www.streetinsider.com - December 5 at 4:25 PM |
| XBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study - StreetInsider.com
www.streetinsider.com - December 4 at 4:27 PM |
 | Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark ... - PR Newswire (press release)
www.prnewswire.com - November 18 at 10:26 AM |
| The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by XBiotech, Inc.
finance.yahoo.com - November 18 at 10:26 AM |
| XBiotech (XBIT) Announces Presentation of Novel Findings for MABp1 in Prevention of Coronary Thrombosis at AHA - StreetInsider.com
www.streetinsider.com - November 16 at 8:57 AM |
 | XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech ...
www.businesswire.com - November 9 at 10:17 AM |
| XBIT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of XBiotech, Inc.
finance.yahoo.com - November 9 at 10:17 AM |
| XBiotech (XBIT) Says Its MABp1 to be Featured in Oral Presentation ... - StreetInsider.com
www.streetinsider.com - November 5 at 8:19 AM |
 | XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
feeds.benzinga.com - November 3 at 12:58 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered ... - GlobeNewswire (press release)
globenewswire.com - October 27 at 10:09 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in XBiotech, Inc. and Set a Lead Plaintiff Deadline of December 26, 2017 -- XBIT
finance.yahoo.com - October 27 at 7:43 AM |
| XBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 Combo with Onivyde and 5-fluorouracil/folinic acid for Treatment of Pancreatic Cancer
www.streetinsider.com - October 20 at 10:33 AM |
 | XBiotech Enters Oversold Territory (XBIT)
www.thestreet.com - October 20 at 10:33 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
finance.yahoo.com - October 20 at 10:33 AM |
| XBiotech (XBIT) Enrolls First Patient in Study Evaluating MABp1 ... - StreetInsider.com
www.streetinsider.com - October 18 at 9:49 PM |
| Comparing Acer Therapeutics (ACER) & XBiotech (XBIT)
www.americanbankingnews.com - October 18 at 2:24 PM |
| XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
finance.yahoo.com - October 18 at 10:53 AM |
| XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board
finance.yahoo.com - October 3 at 3:31 PM |
| XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference
finance.yahoo.com - September 23 at 12:14 PM |
 | XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with
www.nasdaq.com - September 20 at 11:22 AM |
| XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with OnivydeⓇ and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
finance.yahoo.com - September 20 at 11:22 AM |
| Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc.
www.thestreet.com - September 19 at 9:47 AM |
| Contrasting XBiotech (XBIT) & Lexicon Pharmaceuticals (LXRX)
www.americanbankingnews.com - September 15 at 4:34 AM |
| XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis ... - GlobeNewswire (press release)
globenewswire.com - September 7 at 11:29 AM |
XBiotech (NASDAQ:XBIT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
XBiotech (NASDAQ:XBIT) Income Statement, Balance Sheet and Cash Flow Statement
XBiotech (NASDAQ XBIT) Stock Chart for Friday, April, 20, 2018
Loading chart…
